The ASCO Post

The effect of combined hormone replacement therapy (HRT) in increasing a woman’s risk of breast cancer is likely to have been underestimated by a number of previous studies, according to a new prospective study published by Jones et al in the British Journal of Cancer.


Matthew Stenger

As reported in The Lancet Oncology by Zielinski et al, the final results of the phase III TURANDOT trial showed that overall survival with first-line bevacizumab (Avastin)/capecitabine was noninferior vs bevacizumab/paclitaxel in per-protocol analysis among patients with advanced HER2-negative breast cancer.


Fatima Cardoso,

The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical outcome in women with early-stage breast cancer. We sought to provide prospective evidence of the clinical utility of the addition of the 70-gene signature to standard clinical–pathological criteria in selecting patients for adjuvant chemotherapy.


David J. Hunter, M.B., B.S., Sc.D.

A National Research Council report on “precision medicine” explains that the term “refers to the tailoring of medical treatment to the individual characteristics of each patient.” The report goes on to say, “It should be emphasized that in ‘precision medicine’ the word ‘precision’ is being used in a colloquial sense, to mean both ‘accurate’ and ‘precise.’”1 In the colloquial sense, “precision” also implies a high degree of certainty of an outcome, as in “precision-guided missile” or “at what precise time will you arrive?” So will precision medicine usher in an age of diagnostic and prognostic certainty?



Εγγραφείτε στα Newsletter μας και μείνετε ενημερωμένοι!
Συμφωνώ με την πολιτική απορρήτου


Για οποιαδήποτε ερώτηση σας μπορείτε να επικοινωνήσετε μαζί μας στα παρακάτω στοιχεία.